As part of a larger plan to revise regulations on tobacco and nicotine, the U.S. Food and Drug Administration (FDA) is considering limiting the nicotine content of combusted cigarettes in an effort to make them less addictive. In response to FDA’s advance notice of proposed rulemaking on this potential policy, our comments offered advice, drawing from recent economic scholarship, on how the agency could assess a nicotine limit’s costs and benefits.
Related Reading
-
Comments to OMB on Draft Update of Circular A-4
Project Updates / June 20, 2023
-
New Guidance Improves Consideration of Health, Equity, and Environmental Benefits in Regulations
Media Resources / April 6, 2023
-
Revesz Nominated to Lead OMB’s Office of Information and Regulatory Affairs
Media Resources / September 2, 2022
-
Toward Rationality in Oil and Gas Leasing: Building the Toolkit for Programmatic Reforms
Publications / August 6, 2021
-
Statement on Repeal of EPA Cost-Benefit Rule
Media Resources / May 13, 2021